BioSpace News Archive

IntraOp Medical Corporation announced today the first patient enrolled in the Cosmopolitan Trial: A randomized study of single treatment electron-beam intraoperative radiation therapy (IORT) delivered during surgery compared to external beam radiation therapy which is delivered over 3-4 weeks.

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, applauds Biogen’s initiation of BLA (biologics license application) submission to the U.S. Food and Drug Administration (FDA) for aducanumab, its Alzheimer’s disease candidate targeting amyloid beta

GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its first quarter earnings results after market close on Monday, May 4, 2020.

The Junior Science and Humanities Symposium (JSHS), the premier showcase for science, technology, engineering, and math (STEM) research by high school students, is pleased to announce the 2020 winners of the 58th National JSHS competition.

Metagenomics plays an important role in bioremediation as microorganisms are the main agents of bioremediation. Microorganisms are responsible for degradation of environmental pollutants. The metagenome of a contaminated environment includes all the DNA involved in that environment.

The growth of the psoriasis drugs market is attributed to the growing use of topical corticosteroids products and psoriasis treatment across the globe. According to a latest research by the company, the global corticosteroid psoriasis drugs treatment market is expected to account for over US$ 6,509 Mn in terms of value by 2028 end.

Neocis, Inc., the manufacturer of the Yomi Dental Robotics System, is proud to announce that several of their employees are volunteering their personal time and sharing their professional expertise to help The Ventilator Project.

TearLab Corporation (OTCQB: TEAR) (“TearLab” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its 510(k) application for the potential clearance of its TearLab Discovery™ MMP-9 Test, the Company’s next-generation in-vitro diagnostic testing system.

The global market for high content screening is currently witnessing the emergence of several notable trends from the product, application, and industry perspective. Growing concerns of pharmaceutical companies towards toxicity studies is shifting focus on secondary cell screening.

Texas diagnostic company resolves the hurdle of comprehensive antibody testing with its ability to complete up to 500 accurate COVID-19 antibody tests per hour (12,000/day), helping speed the process of getting Texas and the U.S. back to work as quickly and safely as possible